Analytical Immunopharmacology

项目概要-核心A 分析免疫药理学核心（核心A）旨在满足特定药物和生物制品的要求。 每个U19研究项目的治疗开发需求，同时利用 现有City of Hope Comprehensive Cancer Center（COHCCC）核心，无需重复 服务。核心A将与COHCCC核心以及U19密切协作 管理核心和分子特征分析和生物信息学核心（核心B）提供特殊支持 所有拟议的研究项目和U19之间的合作。核心A的总体目标是 协助胶质母细胞瘤治疗网络（GTN）U19项目负责人进行药代动力学（PK）研究， 为支持拟定临床试验而进行的药效学（PD）相关研究。这项工作将 通过利用核心在脑内微透析（ICMD）、分析和治疗方面的重要专业知识， 化学和分析免疫化学，以及其获得最先进的仪器。整体 将通过以下具体目标实现这一目的： 目标1.为U19研究者提供相关神经PK分析的概念和分析支持 (e.g., CNS中药物和代谢物的分析）。核心A向U19调查员提供的支助， 这一目标将包括ICMD神经药代动力学研究的所有方面，包括实验设计、分析方法 开发、样品分析和数据的最终解释。核心A由训练有素的人员组成 并配备了分析仪器，这将是理想的小分子定量分析 (e.g., LC-MS/MS和ICP-MS/MS）。 目标2.为U19研究者提供相关神经PD的概念和分析支持 分析（例如，CNS中药物反应的生物标志物的分析）。核心A向U19提供的支持 这一目标下的研究人员将包括ICMD神经-PD研究的所有方面，包括实验设计， 分析方法开发、样品分析和数据的最终解释。核心A将提供 免疫测定平台的光谱（例如，Luminex和ELISA）在ICMD神经-PD研究背景下， 支持拟议的临床试验。

PROJECT SUMMARY – CORE A The Analytical Immunopharmacology Core (Core A) is designed to meet the specific drug and biologic therapeutic development needs of each of the U19 Research Projects and at the same time draw on the strength of the existing City of Hope Comprehensive Cancer Center (COHCCC) cores without unnecessary duplication of services. Core A will work closely and synergistically with COHCCC cores, as well as with the U19 Administrative Core and the Molecular Profiling and Bioinformatics Core (Core B) to provide exceptional support for all of the proposed Research Projects and inter-U19 collaborations. The overarching goals of Core A are to assist the Glioblastoma Therapeutics Network (GTN) U19 Project Leaders with pharmacokinetic (PK) and pharmacodynamic (PD) correlative studies performed in support of the proposed clinical trials. The work will be accomplished by leveraging the Core’s significant expertise in intracerebral microdialysis (ICMD), analytical chemistry, and analytical immunochemistry, as well as its access to state-of-the-art instrumentation. The overall purpose will be achieved through the following Specific Aims: Aim 1. Provide conceptual and analytical support to U19 investigators for correlative neuro-PK analyses (e.g., analysis of drugs and metabolites in the CNS). Support provided by Core A to U19 investigators under this aim will include all aspects of ICMD neuro-PK studies, including experimental design, analytical method development, sample analysis, and final interpretation of the data. Core A is staffed by highly trained personnel and equipped with analytical instrumentation that will be ideal for the quantitative analyses of small molecules (e.g., LC-MS/MS and ICP-MS/MS). Aim 2. Provide conceptual and analytical support to U19 investigators for their correlative neuro-PD analyses (e.g., analysis of biomarkers of drug response in the CNS). Support provided by Core A to U19 investigators under this aim will include all aspects of ICMD neuro-PD studies, including experimental design, analytical method development, sample analysis, and final interpretation of the data. Core A will provide a spectrum of immunoassay platforms (e.g., Luminex and ELISA) in the context of ICMD neuro-PD studies in support of the proposed clinical trials.